Elafibranor

Elafibranor is a dual PPARalpha/delta agonist (EC50 PPARalpha = 10-20 nM; PPARdelta = 100-150 nM) .1 It was able to decrease plasma triglycerides levels1, increase HDL cholesterol levels in human studies1, and improve hepatic and peripheral insulin sensitivity2. Elafibranor’s antidiabetic effects in db/db were without the adverse cardiac effects seen in PPARgamma agonism.3 Elafibranor has also been shown to have therapeutic promise in the treatment of nonalcoholic steatohepatitis (NASH) .4-6